These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 18375647)

  • 1. A predictive probability design for phase II cancer clinical trials.
    Lee JJ; Liu DD
    Clin Trials; 2008; 5(2):93-106. PubMed ID: 18375647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials.
    Li Y; Mick R; Heitjan DF
    Clin Trials; 2012 Jun; 9(3):293-302. PubMed ID: 22523304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Admissible two-stage designs for phase II cancer clinical trials.
    Jung SH; Lee T; Kim K; George SL
    Stat Med; 2004 Feb; 23(4):561-9. PubMed ID: 14755389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
    Lai X; Zee BC
    Trials; 2015 Jun; 16():250. PubMed ID: 26037094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A confidence function-based posterior probability design for phase II cancer trials.
    Shan M
    Pharm Stat; 2021 May; 20(3):485-498. PubMed ID: 33336856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.
    Berry SM; Broglio KR; Groshen S; Berry DA
    Clin Trials; 2013 Oct; 10(5):720-34. PubMed ID: 23983156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stopping rules for phase II studies.
    Stallard N; Whitehead J; Todd S; Whitehead A
    Br J Clin Pharmacol; 2001 Jun; 51(6):523-9. PubMed ID: 11422011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive designs in critical care trials: a simulation study.
    Li W; Cornelius V; Finfer S; Venkatesh B; Billot L
    BMC Med Res Methodol; 2023 Oct; 23(1):236. PubMed ID: 37853343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian interim analysis of phase II cancer clinical trials.
    Heitjan DF
    Stat Med; 1997 Aug; 16(16):1791-802. PubMed ID: 9280033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
    Ryan EG; Brock K; Gates S; Slade D
    BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian monitoring of phase II trials in cancer chemoprevention.
    Cronin KA; Freedman LS; Lieberman R; Weiss HL; Beenken SW; Kelloff GJ
    J Clin Epidemiol; 1999 Aug; 52(8):705-11. PubMed ID: 10465313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A predictive probability interim design for phase II clinical trials with continuous endpoints.
    Liu M; Dressler EV
    Stat Med; 2018 May; 37(12):1960-1972. PubMed ID: 29611211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical designs for early phases of cancer clinical trials.
    Guan S
    J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
    Johnson VE; Cook JD
    Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing Bayesian early stopping boundaries for phase II clinical trials.
    Jiang L; Yan F; Thall PF; Huang X
    Pharm Stat; 2020 Nov; 19(6):928-939. PubMed ID: 32720462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal futility stopping boundaries for binary endpoints.
    Freitag MM; Li X; Rauch G
    BMC Med Res Methodol; 2024 Mar; 24(1):80. PubMed ID: 38539108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.